United States of America – July 14, 2025 – The Insight Partners proudly announces the release of its new market research report, “Biopharmaceutical Contract Manufacturing Market: An In-depth Analysis of the Global Landscape.” This report delivers a full-spectrum view of the industry, capturing current shifts, emerging trends, and growth forecasts through 2031.

Overview of the Biopharmaceutical Contract Manufacturing Market

The global biopharmaceutical contract manufacturing (CMO) market is expanding rapidly, driven by the surge in biologics and biosimilars production, increasing outsourcing by major pharma players, and breakthroughs in mammalian and microbial expression systems.

Key Findings and Insights

Market Size and Growth

• Market Size in 2024: US$ 40.99 Billion

• Market Size by 2031: US$ 101.05 Billion

• Global CAGR (2025–2031): 13.8%

• Historical Data: 2021–2023

Key Factors Driving Growth:

• Rising demand for cost-efficient drug development and manufacturing

• Expansion of biologics in treatment pipelines

• Increased prevalence of chronic diseases requiring biologics-based therapies

• Tightened regulatory scrutiny prompting quality-focused outsourcing

Market Segmentation

• By Product Type:

  • Biologics

  • Biosimilars

• By Source:

  • Microbial

  • Mammalian

• By Application:

  • Commercial

  • Clinical

• By Therapeutic Area:

  • Oncology

  • Autoimmune Disorders

  • Respiratory Disorders

  • Metabolic Disorders

  • Neurology

  • Infectious Diseases

Spotting Emerging Trends

• Technological Advancements:

  • Single-use bioprocessing systems

  • Continuous manufacturing

  • Automation in upstream/downstream processing

• Changing Client Demands:

  • Big pharma is focusing on agile partnerships with CMOs for speed-to-market

  • Biotech startups increasingly depend on CMOs to avoid heavy infrastructure investments

• Regulatory Landscape:

  • Increased emphasis on GMP compliance

  • Faster approvals via regulatory harmonization, especially in the U.S. and EU

  • Stricter validation requirements for biosimilar production

Growth Opportunities

• Expanding Clinical Trial Pipelines: New drugs in clinical development are boosting demand for clinical-stage manufacturing

• Biologics Dominance: The surge in monoclonal antibodies and gene therapies offers massive production outsourcing potential

• Globalization of Manufacturing Hubs: Asia-Pacific, especially India and South Korea, is becoming a hotspot for cost-efficient CMO services

• Biosimilar Boom: Patent expirations are paving the way for aggressive biosimilar manufacturing

Conclusion

The Biopharmaceutical Contract Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2031 report provides much-needed insight for a company willing to set up its operations in the Biopharmaceutical Contract Manufacturing Market. Since an in-depth analysis of competitive dynamics, the environment, and probable growth path are given in the report, a stakeholder can move ahead with fact-based decision-making in favor of market achievements and enhancement of business opportunities.

About The Insight Partners

The Insight Partners is among the leading market research and consulting firms in the world. We take pride in delivering exclusive reports along with sophisticated strategic and tactical insights into the industry. Reports are generated through a combination of primary and secondary research, solely aimed at giving our clientele a knowledge-based insight into the market and domain. This is done to assist clients in making wiser business decisions. A holistic perspective in every study undertaken forms an integral part of our research methodology and makes the report unique and reliable.

To know more and get access to Sample reports.
https://www.theinsightpartners.com/sample/TIPRE00005512